Point-of-Care Rapid RNA test for Zika
Award amount
$999,916Program and phase
SBIR · Phase II – Direct to Phase IIAward year
2021Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- CROSSLIFE TECHNOLOGIES INC.
- Proposal award date
- 2021-01-15
- Contract end date
- 2022-12-31
- UEI
- LFE6DJ6KL4E5
- Solicitation number
- PA19-272
- Topic code
- 100
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Point of Care HPV 16/18/45 DNA Test for Cervical Cancer
- Rapid Point-of-Care RNA Diagnostic for Dengue Infection
- Point of Care HPV 16/18/45 DNA Test for Cervical Cancer
- Rapid Point-of-Care RNA Diagnostic for Dengue Infection
- Rapid, Point-of-Care Nucleic Acid Test for HCV
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- First-in-class TREM-1 inhibitors for neovascular retinal diseases
- Development of a Novel Biosensor to Accelerate Investigations of the Gut Microbiome
- Magnetic Lipid Nanoprobe Platform for Rapid, Highly-Efficient, and Cost-Effective Isolation of Extracellular Vesicles from Non-Invasive Bodily Fluids
- Scale-up and Manufacturing of STLR-201, an off-the-shelf regenerative therapeutic for Sjogren's syndrome-related dry eye disease
- Integrated assays of single-cell dynamics and molecular phenotype for cell therapy manufacturing
Research funding history
18 SBIR/STTR records share this UEI (2015–2023). Reported award amounts total $12,579,180. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services, National Science Foundation